CoChat
Sign Up
Cited by 177

Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy

Iori, Valentina, Iyer, Anand M., Ravizza, Teresa, Beltrame, Luca, Paracchini, Lara, Marchini, Sergio, Cerovic, Milica, Hill, Cameron +9 more·2017·Neurobiology of Disease
DOI 10.1016/j.nbd.2016.12.007
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2016.12.007

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 64

  1. Ali, A, Dua, Y, Constance, JE, Franklin, MR, Dudek, FE., 2012. A once-per-day, drug-infood protocol for prolonged administration of antiepileptic drugs in animal models. Epilepsia;53:199-206.
  2. Aronica, E, Fluiter, K, Iyer, A, Zurolo, E, Vreijling, J, van Vliet, EA, et al., 2010. Expression pattern of miR-146a, an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy. Eur J Neurosci;31:1100-7.
  3. Aronica, E, Ravizza, T, Zurolo, E, Vezzani, A., 2012. Astrocyte immune response in epilepsy. Glia;60:1258-68.
  4. Balosso, S, Maroso, M, Sanchez-Alavez, M, Ravizza, T, Frasca, A, Bartfai, T, et al., 2008. A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1beta. Brain;131:3256-65.
  5. Balosso, S, Ravizza, T, Pierucci, M, Calcagno, E, Invernizzi, RW, Di Giovanni, G, et al., 2009. Molecular and functional interactions between TNF-alpha receptors and the glutamatergic system in the mouse hippocampus: implications for seizure susceptibility. Neuroscience;161:293-300.
  6. Balosso, S, Liu, J, Bianchi, ME, Vezzani, A., 2014. Disulfide-containing High Mobility Group Box-1 promotes N-methyl-d-aspartate receptor function and excitotoxicity by activating Toll-like receptor 4-dependent signaling in hippocampal neurons. Antioxid Redox Signal;21:1726-1740.
  7. Barker-Haliski, ML, Friedman, D, French, JA, White, HS., 2015. Disease modification in epilepsy: from animal models to clinical applications. Drugs;75:749-67.
  8. Boldin, MP, Taganov, KD, Rao, DS, Yang, L, Zhao, JL, Kalwani, M, et al., 2011. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med;208:1189-201.
  9. Budde, BS, Namavar, Y, Barth, PG, Poll-The, BT, Nurnberg, G, Becker, C, et al., 2008. tRNA splicing endonuclease mutations cause pontocerebellar hypoplasia. Nat Genet;40:1113-8.
  10. Burianova, I, Borecka, K., 2015. Routine therapeutic monitoring of the active metabolite of carbamazepine: Is it really necessary? Clin Biochem;48:866-9.
  11. Devinsky, O, Vezzani, A, Najjar, S, De Lanerolle, NC, Rogawski, MA., 2013. Glia and epilepsy: excitability and inflammation. Trends Neurosci;36:174-84.
  12. Duncan, JS, Sander, JW, Sisodiya, SM, Walker, MC., 2006. Adult epilepsy. Lancet;367:1087-100.
  13. Franklin, KBJ, Paxinos, G., 2008. The mouse brain in stereotaxic coordinates Academic Press, San Diego.
  14. Frigerio, F, Frasca, A, Weissberg, I, Parrella, S, Friedman, A, Vezzani, A, et al., 2012. Long-lasting pro-ictogenic effects induced in vivo by rat brain exposure to serum albumin in the absence of concomitant pathology. Epilepsia;53:1887-1897.
  15. Gasior, M, White, NA, Rogawski, MA., 2007. Prolonged attenuation of amygdala-kindled seizure measures in rats by convection-enhanced delivery of the N-type calcium channel antagonists omega-conotoxin GVIA and omega-conotoxin MVIIA. J Pharmacol Exp Ther;323:458-68.
  16. Gorter, JA, Iyer, A, White, I, Colzi, A, van Vliet, EA, Sisodiya, S, et al., 2014. Hippocampal subregion-specific microRNA expression during epileptogenesis in experimental temporal lobe epilepsy. Neurobiol Dis;62:508-20.
  17. Grabenstatter, HL, Clark, S, Dudek, FE., 2007. Anticonvulsant effects of carbamazepine on spontaneous seizures in rats with kainate-induced epilepsy: comparison of intraperitoneal injections with drug-in-food protocols. Epilepsia; 48:2287-95.
  18. Gu, B, Huang, YZ, He, XP, Joshi, RB, Jang, W, McNamara, JO., 2015. A Peptide Uncoupling BDNF Receptor TrkB from Phospholipase Cgamma1 Prevents Epilepsy Induced by Status Epilepticus. Neuron;88:484-91.
  19. Harward, SC, McNamara, JO., 2014. Aligning animal models with clinical epilepsy: where to begin? Adv Exp Med Biol;813:243-51.
  20. Heinemann, U, Kaufer, D, Friedman, A., 2012. Blood-brain barrier dysfunction, TGFbeta signaling, and astrocyte dysfunction in epilepsy. Glia;60:1251-7.
  21. Iori, V, Maroso, M, Rizzi, M, Iyer, AM, Vertemara, R, Carli, M, et al., 2013. Receptor for Advanced Glycation Endproducts is upregulated in temporal lobe epilepsy and contributes to experimental seizures. Neurobiol Dis;58:102-14.
  22. Iyer, A, Marson, A., 2014. Pharmacotherapy of focal epilepsy. Expert Opin Pharmacother;15:1543-51.
  23. Jimenez-Mateos, EM, Engel, T, Merino-Serrais, P, McKiernan, RC, Tanaka, K, Mouri, G, et al., 2012. Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects. Nat Med;18:1087-94.
  24. Jimenez-Mateos, EM, Henshall, DC., 2013. Epilepsy and microRNA. Neuroscience; 238:218-29.
  25. Jyonouchi, H, Geng, L., 2016. Intractable Epilepsy (IE) and Responses to Anakinra, a Human Recombinant IL-1 Receptor Antagonist (IL-1Ra): Case Reports. Journal of Clinical and Cellular Immunology;7:456-460.
  26. Kenney, L, Kahoud, JR, Vezzani, A, LaFrance-Corey, GR, Ho, M, Muskardin, TW, Gleich, JS, Wirrell, CE, Howe, LC, Payne TE.Super refractory status epilepticus secondary to febrile illness related epilepsy syndrome treated with anakinra. Annals of Neurology, in press .
  27. Keyel, PA., 2014. How is inflammation initiated? Individual influences of IL-1, IL-18 and HMGB1. Cytokine;69:136-45.
  28. Lehmann, SM, Kruger, C, Park, B, Derkow, K, Rosenberger, K, Baumgart, J, et al., 2012. An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat Neurosci;15:827-35.
  29. Leon, CG, Tory, R, Jia, J, Sivak, O, Wasan, KM., 2008. Discovery and development of tolllike receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases. Pharm Res;25:1751-61.
  30. Lepper, PM, Triantafilou, M, O'Neill, LA, Novak, N, Wagner, H, Parker, AE, et al., 2010. Modulation of toll-like receptor signalling as a new therapeutic principle. Mediators Inflamm;2010:705612.
  31. Li, T, Ren, G, Lusardi, T, Wilz, A, Lan, JQ, Iwasato, T, et al., 2008. Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice. J Clin Invest;118:571-82.
  32. Macagno, A, Molteni, M, Rinaldi, A, Bertoni, F, Lanzavecchia, A, Rossetti, C, et al., 2006. A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression. J Exp Med;203:1481-92.
  33. Maroso, M, Balosso, S, Ravizza, T, Liu, J, Aronica, E, Iyer, AM, et al., 2010. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med;16:413-9.
  34. Maroso, M, Balosso, S, Ravizza, T, Iori, V, Wright, CI, French, J, et al., 2011a. Interleukin1beta biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. Neurotherapeutics;8:304-15.
  35. Maroso, M, Balosso, S, Ravizza, T, Liu, J, Bianchi, ME, Vezzani, A., 2011b. Interleukin-1 type 1 receptor/Toll-like receptor signalling in epilepsy: the importance of IL-1beta and high-mobility group box 1. J Intern Med;270:319-26.
  36. McDaniel B, Sheng H, Warner DS, Hedlund LW, Benveniste H., 2001. Tracking brain volume changes in C57BL/6J and ApoE-deficient mice in a model of neurodegeneration: a 5-week longitudinal micro-MRI study. Neuroimage;14:124455.
  37. Mohanraj, R, Brodie, MJ., 2003. Measuring the efficacy of antiepileptic drugs. Seizure;12:413-43.
  38. Mouri, G, Jimenez-Mateos, E, Engel, T, Dunleavy, M, Hatazaki, S, Paucard, A, et al., 2008. Unilateral hippocampal CA3-predominant damage and short latency epileptogenesis after intra-amygdala microinjection of kainic acid in mice. Brain Res;1213:140-51.
  39. Noé, FM, Polascheck, N, Frigerio, F, Bankstahl, M, Ravizza, T, Marchini, S, et al., 2013. Pharmacological blockade of IL-1beta/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy. Neurobiol Dis;59:183-93.
  40. O'Neill, LA., 2008. 'Fine tuning' TLR signaling. Nat Immunol;9:459-61.
  41. Omran, A, Peng, J, Zhang, C, Xiang, QL, Xue, J, Gan, N, et al., 2012. Interleukin-1beta and microRNA-146a in an immature rat model and children with mesial temporal lobe epilepsy. Epilepsia;53:1215-24.
  42. Pedrazzi, M, Averna, M, Sparatore, B, Patrone, M, Salamino, F, Marcoli, M, et al., 2012. Potentiation of NMDA receptor-dependent cell responses by extracellular high mobility group box 1 protein. PLoS One;7:e44518.
  43. Pitkanen, A, Sutula, TP., 2002. Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurol;1:173-81.
  44. Prabowo, AS, van Scheppingen, J, Iyer, AM, Anink, JJ, Spliet, WG, van Rijen, PC, et al., 2015. Differential expression and clinical significance of three inflammation-related microRNAs in gangliogliomas. J Neuroinflammation;12:97.
  45. Quinn, SR, O'Neill, LA., 2011. A trio of microRNAs that control Toll-like receptor signalling. Int Immunol;23:421-5.
  46. Ramakers, C, Ruijter, JM, Deprez, RH, Moorman, AF., 2003. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett;339:626.
  47. Ravizza, T, Lucas, SM, Balosso, S, Bernardino, L, Ku, G, Noé, F, Malva, J, Randle, JC, Allan, S, Vezzani A., 2006. Inactivation of caspase-1 in rodent brain: a novel anticonvulsive strategy. Epilepsia;47:1160-8.
  48. Rossetti, AO, Alvarez, V, Januel, JM, Burnand, B., 2013. Treatment deviating from guidelines does not influence status epilepticus prognosis. J Neurol;260:421-8.
  49. Ruijter, JM, Ramakers, C, Hoogaars, WM, Karlen, Y, Bakker, O, van den Hoff, MJ, et al., 2009. Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res;37:e45.
  50. Sarkis, RA, Jehi, L, Bingaman, W, Najm, IM., 2012. Seizure worsening and its predictors after epilepsy surgery. Epilepsia;53:1731-8.
  51. Schmidt, D, Sillanpaa, M., 2005. Does surgery prevent worsening of epilepsy? Epilepsia;54:391.
  52. Shinoda, S, Schindler, CK, Meller, R, So, NK, Araki, T, Yamamoto, A, et al., 2004. Bim regulation may determine hippocampal vulnerability after injurious seizures and in temporal lobe epilepsy. J Clin Invest;113:1059-68.
  53. Temkin, NR., 2001. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia;42:515-24.
  54. Tsai, MH, Chuang, YC, Chang, HW, Chang, WN, Lai, SL, Huang, CR, et al., 2009. Factors predictive of outcome in patients with de novo status epilepticus. QJM;102:57-62.
  55. van Scheppingen, J, Iyer, AM, Prabowo, AS, Muhlebner, A, Anink, JJ, Scholl, T, et al., 2016. Expression of microRNAs miR21, miR146a, and miR155 in tuberous sclerosis complex cortical tubers and their regulation in human astrocytes and SEGA-derived cell cultures. Glia;64:1066-82.
  56. Vezzani, A, Moneta, D, Conti, M, Richichi, C, Ravizza, T, De Luigi, A, et al., 2000. Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. Proc Natl Acad Sci U S A;97:11534-9.
  57. Vezzani, A, French, J, Bartfai, T, Baram, TZ., 2011a. The role of inflammation in epilepsy. Nat Rev Neurol;7:31-40.
  58. Vezzani, A, Maroso, M, Balosso, S, Sanchez, MA, Bartfai, T., 2011b. IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. Brain Behav Immun;25:1281-9.
  59. Vezzani, A, Friedman, A, Dingledine, RJ., 2013. The role of inflammation in epileptogenesis. Neuropharmacology;69:16-24.
  60. Vezzani, A., 2015. Anti-inflammatory drugs in epilepsy: does it impact epileptogenesis? Expert Opin Drug Saf;14:583-92.
  61. Vezzani, A, Dingledine, R, Rossetti, AO., 2015a. Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application. Expert Rev Neurother;15:1081-92.
  62. Viviani, B, Bartesaghi, S, Gardoni, F, Vezzani, A, Behrens, MM, Bartfai, T, et al., 2003. Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J Neurosci;23:8692-700.
  63. Yi, X, Manickam, DS, Brynskikh, A, Kabanov, AV., 2014. Agile delivery of protein therapeutics to CNS. J Control Release;190:637-63.
  64. Zeng, Z, Gong, H, Li, Y, Jie, K, Ding, C, Shao, Q, et al., 2013. Upregulation of miR-146a contributes to the suppression of inflammatory responses in LPS-induced acute lung injury. Exp Lung Res;39:275-82.

Cited by

Sorted by citations

Authors
Iori, V., Iyer, A. M., Ravizza, T., Beltrame, L., Paracchini, L., Marchini, S., Cerovic, M., Hill, C., Ferrari, M., Zucchetti, M., Molteni, M., Rossetti, C., Brambilla, R., Steve White, H., D'Incalci, M., Aronica, E., & Vezzani, A.
Venue
Neurobiology of Disease
Publisher
Elsevier BV
Published
2017-03
Volume
99
Pages
12-23
ISSN
0969-9961
DOI
10.1016/j.nbd.2016.12.007
Cited by
177
References
6
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • Fondazione Umberto Veronesi
  • Seventh Framework Programme (602102, 602391)
  • Hersenstichting (NF-13-1VI)
  • Fondazione Antonio Carlo Monzino

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review